Developing Strategies on Emerging Issues
Supply Chain challenges continued through 2021.
Throughout the year, CHPA worked with federal and state government authorities, specifically in response to President Joe Biden’s February 24th Executive Order (EO), designed to strengthen existing Buy American policies for the federal government. CHPA has provided ongoing guidance to the White House and Capitol Hill on supply chain matters.
Additionally, CHPA offered a three-part webinar series this year, with a variety of concepts to help advance our members’ businesses through their supply chain and workforce challenges.
As the supply chain issues and challenges drag on, CHPA will continue our work bringing together logistics, supply chain, and operations professionals from our member companies, to proactively improve the current climate through legislative and educational efforts.
Additional webinar content is available on demand, to help members navigate labor shortages, sustainability and trucking issues.
A Powerful Evidence Base to Defend Acetaminophen in Prop 65
CHPA, and members of the Prop 65 Acetaminophen Task Group, took the opportunity in 2021 to build a substantial and compelling base of research published in a respected peer-reviewed journal to defend acetaminophen’s safety. Seven papers were completed and included in a special issue of the journal, Regulatory, Toxicology & Pharmacology, released in the fall of 2021; the articles conclude that “these studies collectively confirm that acetaminophen is not a carcinogenic hazard at any dose level, consistent with previous conclusions of key scientific bodies.” The Task Group is now engaging California’s key leaders in healthcare and government to promote the collective findings of this new research to defend the safe use of acetaminophen.
In other Prop 65 related news, CHPA signed on to comments from the California Chamber of Commerce and the Consumer Brands Association objecting to proposed amendments from the California Office of Environmental Health Hazard Assessment which would adopt a new safe harbor warning (cancer) regulation for exposure to glyphosate in consumer products.
Scott Melville Advocates for a CBD Pathway on Capitol Hill as Senate Introduces CBD Legislation
H.R. 841, the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021, introduced by Reps. Kurt Schrader (D-Ore.) and Morgan Griffith (R-Va.), is critical to protecting consumers and to providing long-term certainty in the hemp-derived CBD market.
Earlier this year, CHPA President & CEO Scott Melville spoke at an event on Capitol Hill about H.R. 841. The event was hosted by Congressman Kurt Schrader (D-Ore.), and included farmers, CBD manufacturers, and the leading trade associations in the dietary supplement marketplace, including CHPA. Melville discussed growing consumer demand for CBD products, the challenges for legitimate actors in an unregulated market, and the price of FDA’s inaction.
New Territory for a Successful Strategy on Loperamide
Through our campaign, www.loperamidesafety.org, CHPA continues to work alongside numerous national organizations — like the American Association of Poison Control Centers, the American Society of Clinical Toxicology, and the American College of Emergency Physicians— to educate HCPs and at-risk consumers, while also emphasizing the importance of OTC access to this essential medicine.
In May 2021, FDA announced its intent to prepare an environmental impact statement (EIS) to evaluate the potential environmental effects of revised conditions for marketing certain OTC sunscreens. CHPA submitted joint comments with the Personal Care Products Council (PCPC) to FDA June 2021, supporting a categorical exclusion for the sunscreen active ingredients oxybenzone and octinoxate, asking FDA to clearly articulate the need for an EIS and noting that an EIS should have no impact on safety determinations for sunscreen ingredients.
Diversity, Equity, and Inclusion
CHPA — along with many other organizations, companies, and individuals — has emerged to do its part and take bolder steps to address inequity, expand access, and foster inclusive environments. We took bold, swift actions, establishing two committees for diversity, equity, and inclusion (DEI) — a board-level steering committee and an internal, staff-led inclusion, diversity, equity, acceptance (IDEA) committee — to work together to identify tangible steps that CHPA, and its member companies, could take to help promote a more inclusive industry and to support broader efforts to ensure equity for all Americans.
Now well-underway, we’ve generated project ideas in the areas of Education & Training, Initiatives & Community Outreach, NextGeneration Pharma Leaders, and Policy. Two consultants, Mariama Boney, Achieve More LLC, and Barbara Adams, GAR Diversity Consulting, have been engaged to advise on our overall programs and a diversity survey of members.
We invite you to check out our website, which has been updated to detail the many projects already in-progress. Importantly, we're pleased to offer members CHPA's first-ever DEI Resource Guide, a framework that you can use to customize a DEI initiative for your own organization.
CHPA stands ready to assist you, and work together, to realize a more inclusive consumer healthcare industry. We hope you’ll join us!